Biomarkers for Early Detection, Prognosis, and Therapeutics of Esophageal Cancers

Esophageal cancer (EC) is the deadliest cancer worldwide, with a 92% annual mortality rate per incidence. Esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) are the two major types of ECs, with EAC having one of the worst prognoses in oncology. Limited screening techniques and a lack of molecular analysis of diseased tissues have led to late-stage presentation and very low survival durations. The five-year survival rate of EC is less than 20%. Thus, early diagnosis of EC may prolong survival and improve clinical outcomes. Cellular and molecular biomarkers are used for diagnosis. At present, esophageal biopsy during upper endoscopy and histopathological analysis is the standard screening modality for both ESCC and EAC. However, this is an invasive method that fails to yield a molecular profile of the diseased compartment. To decrease the invasiveness of the procedures for diagnosis, researchers are proposing non-invasive biomarkers for early diagnosis and point-of-care screening options. Liquid biopsy involves the collection of body fluids (blood, urine, and saliva) non-invasively or with minimal invasiveness. In this review, we have critically discussed various biomarkers and specimen retrieval techniques for ESCC and EAC.

[1]  Ting-zhuang Yi,et al.  Identification of potential biomarkers in Barrett’s esophagus derived esophageal adenocarcinoma , 2021, Scientific Reports.

[2]  Ming-Chin Lin,et al.  Deep Learning for the Diagnosis of Esophageal Cancer in Endoscopic Images: A Systematic Review and Meta-Analysis , 2022, Cancers.

[3]  D. Agrawal,et al.  Non-Coding RNAs in Regulating Plaque Progression and Remodeling of Extracellular Matrix in Atherosclerosis , 2022, International journal of molecular sciences.

[4]  Sen Li,et al.  Machine Learning and Novel Biomarkers Associated with Immune Infiltration for the Diagnosis of Esophageal Squamous Cell Carcinoma , 2022, Journal of oncology.

[5]  J. Qin,et al.  Urinary protein biomarker panel predicts esophageal squamous carcinoma from control cases and other tumors , 2022, Esophagus.

[6]  G. Kim,et al.  MicroRNA Expression in Plasma of Esophageal Squamous Cell Carcinoma Patients , 2022, Journal of Korean medical science.

[7]  F. He,et al.  Current advances and future perspectives on the functional roles and clinical implications of circular RNAs in esophageal squamous cell carcinoma: more influential than expected , 2022, Biomarker Research.

[8]  P. Cravedi,et al.  Noninvasive biomarkers for the diagnosis and management of autoimmune hepatitis , 2022, Hepatology.

[9]  N. Bhattarai,et al.  Serum proteomics unveil characteristic protein diagnostic biomarkers and signaling pathways in patients with esophageal squamous cell carcinoma , 2022, Clinical proteomics.

[10]  Tian Yang,et al.  Serum DSG2 as a potential biomarker for diagnosis of esophageal squamous cell carcinoma and esophagogastric junction adenocarcinoma , 2022, Bioscience reports.

[11]  S. Murthy,et al.  Esophageal adenocarcinoma: A dire need for early detection and treatment , 2022, Cleveland Clinic Journal of Medicine.

[12]  C. Gheorghe,et al.  Liquid Biopsy in Squamous Cell Carcinoma of the Esophagus and of the Head and Neck , 2022, Frontiers in Medicine.

[13]  F. Dumoulin,et al.  Artificial Intelligence in the Management of Barrett’s Esophagus and Early Esophageal Adenocarcinoma , 2022, Cancers.

[14]  H. Yip,et al.  Performance of screening tests for Oesophageal Squamous Cell Carcinoma: a systematic review and meta-analysis. , 2022, Gastrointestinal endoscopy.

[15]  A. Teschendorff,et al.  Novel epigenetic network biomarkers for early detection of esophageal cancer , 2022, Clinical epigenetics.

[16]  B. Helmink,et al.  Hallmarks of response, resistance, and toxicity to immune checkpoint blockade , 2022, Cell.

[17]  A. Bansal,et al.  Quantitative proteomic profiling of esophageal adenocarcinoma tumors to assess prevalence of approved targets and elucidate novel biomarkers. , 2022, Journal of Clinical Oncology.

[18]  S.-C. Jim Yeung,et al.  A signature of saliva-derived exosomal small RNAs as predicting biomarker for esophageal carcinoma: a multicenter prospective study , 2022, Molecular Cancer.

[19]  N. Waddell,et al.  ctDNA as a biomarker of progression in oesophageal adenocarcinoma , 2021, ESMO open.

[20]  F. Meng,et al.  Salivary microbiota may predict the presence of esophageal squamous cell carcinoma , 2021, Genes & diseases.

[21]  Gitanjali Goyal,et al.  Potential role of noninvasive biomarkers during liver fibrosis , 2021, World journal of hepatology.

[22]  D. Agrawal,et al.  S431 Proteomic Assay for Barrett’s Esophagus Progression: A Multi-Institutional Retrospective Study , 2021, American Journal of Gastroenterology.

[23]  Jun Liu,et al.  Biomarkers for the prediction of esophageal cancer neoadjuvant chemoradiotherapy response: a systemic review. , 2021, Critical reviews in oncology/hematology.

[24]  S. Billan,et al.  Pembrolizumab–chemotherapy for advanced oesophageal cancer , 2021, The Lancet.

[25]  Sung-Bae Kim,et al.  Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study , 2021, The Lancet.

[26]  D. Agrawal,et al.  Current state of prognostication, therapy and prospective innovations for Barrett's-related esophageal adenocarcinoma: a literature review. , 2021, Journal of gastrointestinal oncology.

[27]  Vikrant Rai,et al.  The Role of Microbiota in the Pathogenesis of Esophageal Adenocarcinoma , 2021, Biology.

[28]  S. Markar,et al.  Clinical utility and applicability of circulating tumor DNA testing in esophageal cancer: a systematic review and meta-analysis , 2021, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[29]  S. Hong,et al.  Current Status of Image-Enhanced Endoscopy for Early Identification of Esophageal Neoplasms , 2021, Clinical endoscopy.

[30]  A. Madabhushi,et al.  Artificial Intelligence in Surveillance of Barrett's Esophagus , 2021, Cancer Research.

[31]  M. Fassan,et al.  Modern Diagnosis of Early Esophageal Cancer: From Blood Biomarkers to Advanced Endoscopy and Artificial Intelligence , 2021, Cancers.

[32]  H. Matsubara,et al.  Development of imaging biomarker for esophageal cancer using intravoxel incoherent motion MRI , 2021, Esophagus.

[33]  F. Barba,et al.  Biomonitoring of Multiple Mycotoxins in Urine by GC–MS/MS: A Pilot Study on Patients with Esophageal Cancer in Golestan Province, Northeastern Iran , 2021, Toxins.

[34]  Xiaoshan Feng,et al.  Using a machine learning approach to identify key prognostic molecules for esophageal squamous cell carcinoma , 2021, BMC Cancer.

[35]  H. Nagase,et al.  Cell-free microRNA-1246 in different body fluids as a diagnostic biomarker for esophageal squamous cell carcinoma , 2021, PloS one.

[36]  A. Cervantes,et al.  Checkpoint inhibitors for gastroesophageal cancers: Dissecting heterogeneity to better understand their role in first line and adjuvant therapy. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  Chun Chen,et al.  Application of machine learning approaches to predict the 5-year survival status of patients with esophageal cancer , 2021 .

[38]  D. Katzka,et al.  Endoscopic Screening for Barrett's Esophagus and Esophageal Adenocarcinoma: Rationale, Candidates, and Challenges. , 2021, Gastrointestinal endoscopy clinics of North America.

[39]  Tamaki Yamada,et al.  Urinary microRNA biomarkers for detecting the presence of esophageal cancer , 2020, Scientific Reports.

[40]  T. Zhai,et al.  Imaging biomarkers of contrast-enhanced computed tomography predict survival in oesophageal cancer after definitive concurrent chemoradiotherapy , 2020, Radiation oncology.

[41]  Tao Yu,et al.  Case Report: Herceptin as a Potentially Valuable Adjuvant Therapy for a Patient With Human Epidermal Growth Factor Receptor 2-Positive Advanced Esophageal Squamous Cell Carcinoma , 2021, Frontiers in Oncology.

[42]  C. S. Bang,et al.  Computer-aided diagnosis of esophageal cancer and neoplasms in endoscopic images: a systematic review and meta-analysis of diagnostic test accuracy. , 2020, Gastrointestinal endoscopy.

[43]  Jian Zhu,et al.  Pretreatment CT-Based Radiomics Signature as a Potential Imaging Biomarker for Predicting the Expression of PD-L1 and CD8+TILs in ESCC , 2020, OncoTargets and therapy.

[44]  Luis A. de Souza,et al.  Endoscopic prediction of submucosal invasion in Barrett’s cancer with the use of artificial intelligence: a pilot study , 2020, Endoscopy.

[45]  C. Palm,et al.  Standalone performance of artificial intelligence for upper GI neoplasia: a meta-analysis , 2020, Gut.

[46]  Luming Huang,et al.  Artificial intelligence technique in detection of early esophageal cancer , 2020, World journal of gastroenterology.

[47]  Vanessa L. Horner,et al.  Gastrointestinal cancers: current biomarkers in esophageal and gastric adenocarcinoma. , 2020, Translational gastroenterology and hepatology.

[48]  P. Bhosale,et al.  Role of precision imaging in esophageal cancer , 2020, Journal of thoracic disease.

[49]  Dongsheng Xu,et al.  Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors , 2020, Biomarker Research.

[50]  C. Richards,et al.  Longitudinal monitoring of circulating tumour DNA improves prognostication and relapse detection in gastroesophageal adenocarcinoma , 2020, British Journal of Cancer.

[51]  Hong Zhao,et al.  Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials , 2020, Therapeutic advances in medical oncology.

[52]  W. Leung,et al.  Accuracy of artificial intelligence-assisted detection of upper GI lesions: a systematic review and meta-analysis. , 2020, Gastrointestinal endoscopy.

[53]  K. Chiam,et al.  Serum outperforms plasma in small extracellular vesicle microRNA biomarker studies of adenocarcinoma of the esophagus , 2020, World journal of gastroenterology.

[54]  K. Lam,et al.  Liquid Biopsy Serial Monitoring of Treatment Responses and Relapse in Advanced Esophageal Squamous Cell Carcinoma , 2020, Cancers.

[55]  Yiwei Xu,et al.  Blood-based biomarkers for early detection of esophageal squamous cell carcinoma , 2020, World journal of gastroenterology.

[56]  Michell Lopez,et al.  Esophageal Cancer: An Updated Surveillance Epidemiology and End Results Database Analysis , 2020, World journal of oncology.

[57]  H. Baba,et al.  Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers , 2020, British Journal of Cancer.

[58]  M. Rugge,et al.  Circulating microRNA expression profiling revealed miR-92a-3p as a novel biomarker of Barrett's carcinogenesis. , 2020, Pathology, research and practice.

[59]  B. Takkouche,et al.  Salivary biomarkers for cancer diagnosis: a meta-analysis , 2020, Annals of medicine.

[60]  N. Merrett,et al.  Association of Biomarkers for Human Papillomavirus With Survival Among Adults With Barrett High-grade Dysplasia and Esophageal Adenocarcinoma. , 2020, JAMA network open.

[61]  Yuyu Qiu,et al.  Discovery of Novel Prognostic Biomarkers and Therapeutic Targets for Esophageal Cancer , 2020 .

[62]  P. Sharma,et al.  Circulating human papillomavirus DNA detection in Barrett's dysplasia and esophageal adenocarcinoma. , 2019, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[63]  Mingyao Liu,et al.  Chemokines and their receptors as biomarkers in esophageal cancer , 2019, Esophagus.

[64]  R. Gurski,et al.  Neutrophil-Lymphocyte Ratio as a Marker of Progression from Non-Dysplastic Barrett’s Esophagus to Esophageal Adenocarcinoma: a Cross-Sectional Retrospective Study , 2019, Journal of Gastrointestinal Surgery.

[65]  Jian Zhu,et al.  Prognostic Value of Texture Analysis Based on Pretreatment DWI-Weighted MRI for Esophageal Squamous Cell Carcinoma Patients Treated With Concurrent Chemo-Radiotherapy , 2019, Front. Oncol..

[66]  B. Berman,et al.  Master transcription factors form interconnected circuitry and orchestrate transcriptional networks in oesophageal adenocarcinoma , 2019, Gut.

[67]  Lincoln D. Stein,et al.  Detection of Circulating Tumor DNA in Plasma: A Potential Biomarker for Esophageal Adenocarcinoma. , 2019, The Annals of thoracic surgery.

[68]  H. Matsubara,et al.  Imaging biomarkers for the treatment of esophageal cancer , 2019, World journal of gastroenterology.

[69]  O. Bodger,et al.  Developing a blood-based gene mutation assay as a novel biomarker for oesophageal adenocarcinoma , 2019, Scientific Reports.

[70]  T. Zander,et al.  HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma , 2019, BMC Cancer.

[71]  Hongwei Zhang,et al.  Advances in prognostic biomarkers for esophageal cancer , 2018, Expert review of molecular diagnostics.

[72]  L. Fashoyin-Aje,et al.  FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD‐L1 , 2018, The oncologist.

[73]  Ke Li,et al.  Exploring potential biomarkers of early stage esophageal squamous cell carcinoma in pre- and post-operative serum metabolomic fingerprint spectrum using 1H-NMR method. , 2019, American journal of translational research.

[74]  T. Zander,et al.  HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma , 2019, BMC Cancer.

[75]  Na-Lin Lai,et al.  Cetuximab for esophageal cancer: an updated meta-analysis of randomized controlled trials , 2018, BMC Cancer.

[76]  K. Chiam,et al.  ASO Author Reflections: Predicting the Response of Esophageal Adenocarcinoma to Chemoradiotherapy Before Surgery Using MicroRNA Biomarkers Offers Hope to Improve Outcomes by Tailoring Treatment to Predicted Responses , 2018, Annals of Surgical Oncology.

[77]  J. Sicklick,et al.  Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma , 2018, Clinical Cancer Research.

[78]  D. Agrawal,et al.  Polymorphisms of Genes Related to Function and Metabolism of Vitamin D in Esophageal Adenocarcinoma , 2018, Journal of Gastrointestinal Cancer.

[79]  N. Merrett,et al.  Survival Rates for Patients With Barrett High-grade Dysplasia and Esophageal Adenocarcinoma With or Without Human Papillomavirus Infection , 2018, JAMA network open.

[80]  Tao-Tao Liu,et al.  Diagnostic and Prognostic Value of Circulating MicroRNAs for Esophageal Squamous Cell Carcinoma: a Systematic Review and Meta-analysis , 2018, Journal of Cancer.

[81]  P. Philip,et al.  Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial , 2018, JAMA oncology.

[82]  D. Agrawal,et al.  Discovery of Novel and Clinically Relevant Markers in Formalin-Fixed Paraffin-Embedded Esophageal Cancer Specimen , 2018, Front. Oncol..

[83]  A. Barbour,et al.  Serum glycoprotein biomarker validation for esophageal adenocarcinoma and application to Barrett’s surveillance , 2018, bioRxiv.

[84]  Z. Tian,et al.  Identification of the key transcription factors in esophageal squamous cell carcinoma. , 2018, Journal of thoracic disease.

[85]  Xu Zhang,et al.  Anaphylatoxin C3a: A potential biomarker for esophageal cancer diagnosis. , 2017, Molecular and clinical oncology.

[86]  Robert A. Smith,et al.  Liquid Biopsy for Investigation of Cancer DNA in Esophageal Adenocarcinoma: Cell-Free Plasma DNA and Exosome-Associated DNA. , 2018, Methods in molecular biology.

[87]  M. Guan,et al.  Ligand-dependent EphA7 signaling inhibits prostate tumor growth and progression , 2017, Cell Death & Disease.

[88]  D. Agrawal,et al.  Neoadjuvant Therapy for Esophageal Adenocarcinoma in the Community Setting—Practice and Outcomes , 2017, Front. Oncol..

[89]  M. Socinski,et al.  First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[90]  Jiang Du,et al.  Analysis of salivary microRNA expression profiles and identification of novel biomarkers in esophageal cancer , 2017, Oncology letters.

[91]  Guoliang Zhang,et al.  Non-coding RNAs: new biomarkers and therapeutic targets for esophageal cancer , 2017, Oncotarget.

[92]  D. Donoghue,et al.  The importance of regulatory ubiquitination in cancer and metastasis , 2017, Cell cycle.

[93]  J. Ajani,et al.  D-mannose: a novel prognostic biomarker for patients with esophageal adenocarcinoma , 2017, Carcinogenesis.

[94]  G. Dakubo Esophageal Cancer Biomarkers in Circulation , 2017 .

[95]  K. Takasaki,et al.  CYFRA 21-1 as a tumor marker for squamous cell carcinoma of the esophagus. , 2017, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[96]  Thomas D. Wang,et al.  Genomic similarity between gastroesophageal junction and esophageal Barrett's adenocarcinomas , 2016, Oncotarget.

[97]  G. Dakubo Cancer Biomarkers in Body Fluids , 2023, Cambridge International Law Journal.

[98]  A. Behrens,et al.  Diagnostics and Early Diagnosis of Esophageal Cancer , 2015, Visceral Medicine.

[99]  D. Agrawal,et al.  Epigenetics in the Pathogenesis of Esophageal Adenocarcinoma , 2015, Clinical and translational science.

[100]  Joel H Rubenstein,et al.  Epidemiology, Diagnosis, and Management of Esophageal Adenocarcinoma. , 2015, Gastroenterology.

[101]  M. Arnal,et al.  Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. , 2015 .

[102]  Michael S. Goldberg,et al.  Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma , 2015, Cancer Immunology Research.

[103]  G. Freeman,et al.  Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma , 2015, Cancer Immunology Research.

[104]  George C. Mayne,et al.  Circulating Serum Exosomal miRNAs As Potential Biomarkers for Esophageal Adenocarcinoma , 2015, Journal of Gastrointestinal Surgery.

[105]  Masayuki Watanabe Risk factors and molecular mechanisms of esophageal cancer: differences between the histologic subtypes , 2015 .

[106]  A. Ribas,et al.  Anti-programmed cell death protein-1/ligand-1 therapy in different cancers , 2015, British Journal of Cancer.

[107]  María José Domper Arnal,et al.  Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. , 2015, World journal of gastroenterology.

[108]  Wan-Li Liu,et al.  Establishment of using serum YKL-40 and SCCA in combination for the diagnosis of patients with esophageal squamous cell carcinoma , 2014, BMC Cancer.

[109]  S. Misra,et al.  Esophageal cancer: A Review of epidemiology, pathogenesis, staging workup and treatment modalities. , 2014, World journal of gastrointestinal oncology.

[110]  J. Dou,et al.  A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways , 2014, Cell Death and Disease.

[111]  D. Lenschow,et al.  The Antiviral Activities of ISG15 , 2013, Journal of Molecular Biology.

[112]  A. Sharma,et al.  Receptor for Advanced Glycation End Products (RAGE) on iNKT Cells Mediates Lung Ischemia–Reperfusion Injury , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[113]  Dongfeng Li,et al.  Salivary MicroRNAs as Promising Biomarkers for Detection of Esophageal Cancer , 2013, PloS one.

[114]  Jun Yang,et al.  A Dual Role of Strigolactones in Phosphate Acquisition and Utilization in Plants , 2013, International journal of molecular sciences.

[115]  Feiyan Lin,et al.  Overexpression of S100P promotes colorectal cancer metastasis and decreases chemosensitivity to 5-FU in vitro , 2013, Molecular and Cellular Biochemistry.

[116]  Zijun Xie,et al.  Saliva supernatant miR-21: a novel potential biomarker for esophageal cancer detection. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[117]  H. J. Cha,et al.  Apoptosis-related mRNA expression profiles of ovarian cancer cell lines following cisplatin treatment. , 2010, Journal of gynecologic oncology.

[118]  D. Haines,et al.  Ubiquitin and cancer: new discussions for a new journal. , 2010, Genes & cancer.

[119]  Robert E. Brown,et al.  Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NF-kappaB pathways in human gastric adenocarcinoma. , 2008, Annals of clinical and laboratory science.

[120]  J. Isola,et al.  The calcium-binding protein S100P in normal and malignant human tissues , 2008, BMC clinical pathology.

[121]  Peter D Siersema,et al.  Esophageal cancer. , 2008, Gastroenterology clinics of North America.

[122]  E. Wolf,et al.  Monozygotic Twin Model Reveals Novel Embryo-Induced Transcriptome Changes of Bovine Endometrium in the Preattachment Period1 , 2006, Biology of reproduction.

[123]  M. Azuma,et al.  Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer , 2005, Clinical Cancer Research.

[124]  C. Pickart,et al.  Ubiquitin: structures, functions, mechanisms. , 2004, Biochimica et biophysica acta.

[125]  T. Suter,et al.  Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. , 2004, Breast.

[126]  J. Baraban,et al.  ERK and p38 Inhibit the Expression of 4E-BP1 Repressor of Translation through Induction of Egr-1* , 2003, Journal of Biological Chemistry.

[127]  J C Reed,et al.  Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses. , 2001, Molecular cell.

[128]  Zhijian J. Chen,et al.  Activation of the IκB Kinase Complex by TRAF6 Requires a Dimeric Ubiquitin-Conjugating Enzyme Complex and a Unique Polyubiquitin Chain , 2000, Cell.

[129]  D. Kelleher,et al.  DAD1, the defender against apoptotic cell death, is a subunit of the mammalian oligosaccharyltransferase. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[130]  B. Korant,et al.  Molecular characterization of the interferon-induced 15-kDa protein. Molecular cloning and nucleotide and amino acid sequence. , 1986, The Journal of biological chemistry.

[131]  M. Pestel [Chemotherapy of advanced cancers]. , 1960, Concours medical.